Patron-in-Chief, Victorian Governor, the Honourable Linda Dessau AC.

Running to Save Lives

Sponsor Professor Robert Power on his 65th birthday marathon, and support Burnet’s life-saving international programs. Donate today.

Donate now and help the vulnerable communities Burnet serves.

Support Our Work

Eliminate Malaria

We are committed to making a major contribution in efforts to eliminate malaria as a public health threat, particularly in our region.

One of the leading causes of mortality and morbidity globally, malaria was responsible for around 438,000 deaths and 214 million clinical cases in 2015. An estimated 3.2 billion people are at risk of the disease, with young children and pregnant women most affected.

A two-way pipeline will be created where our research discoveries can be tested in the field, and field programs inform discovery research through our long-standing connections with vulnerable target populations, especially in Papua New Guinea and Myanmar.

Through this program, Burnet will contribute to:

reaching the WHO elimination targets of a 90 percent reduction in malaria incidence and mortality through an active program of basic, discovery and translational research and in-field education, prevention and treatment programs.
supporting country programs in our region that assist WHO in reaching targets of elimination in at least 35 countries by 2030.

Download

Disease Elimination Strategy (1.2 MB)

Contact Details

Professor James Beeson

Deputy Director (People); Head of Malaria Research: Immunity, Vaccines and New Therapies Laboratory; Adjunct Professor Monash University

Telephone

+61385062442

Email

james.beeson@burnet.edu.au

Projects

Antibody engineering to study responses mediating protective immunity
This project will involve engineering antibodies against malaria parasite proteins.
Antibody mAbs to destroy infection: engineering the next generation treatments
Applying discoveries from our cancer mAb program to neutralize and destroy pathogens.
Clinical studies on malaria
The negative consequences of malaria and how to prevent them in children and pregnant women.
Decision science using Optima
Research and applications across disease areas to improve allocative efficiency.
Developing new antimalarial drugs that block protein trafficking
Developing new antimalarial drugs that block protein trafficking and host cell modification.
Developing new tests for malaria elimination: G6PD deficiency
This project focuses on the development of new G6PD deficiency diagnostics.
Developing vaccines against malaria
This project aims to identify key antigens and specific epitopes that are targets of protective immunity.
Discovering the mechanisms and targets of immunity against malaria
Identifying the key targets of protective immunity in people who live in malaria-endemic regions.
Effectiveness of repellent on malaria incidence in SE Myanmar
A project to determine whether repellent delivered by volunteers will reduce malaria incidence.
FcgR Function in cellular responses to malaria parasites
Understanding how antibodies protect against malaria is crucial to vaccine development.
Functional antibody responses to malaria vaccine candidates
Understanding how functional immunity develops to potential malaria vaccine candidates.
HBMM: Home-based management of malaria in PNG
Making malaria diagnostics and treatments available at village-level in rural PNG.
Host red blood cell modification sustains the virulence of malaria parasites
Understanding how malaria parasites modify their human host cells to inform new antimalarials.
HS-RDT MiP: Clinical Performance of HRP2 Rapid Diagnostic Test for Malaria Diagnosis in Pregnant Women in PNG
This project will compare the performance of novel high sensitivity Plasmodium falciparum rapid diagnostic tests with conventional malaria rapid diagnostic tests in pregnant women in Papua New Guinea
Immunity to malaria during pregnancy
How are pregnant women affected by infectious diseases such as malaria?
Immunity, drug efficacy and spread of antimalarial drug resistance
Identifying immune biomarkers to predict antimalarial efficacy is essential.
Major advances in understanding malaria immunity and biology
Identifying key targets of immunity, the mechanisms mediating immunity, and how it is acquired.
Mechanism of antimalarial drug action
Understanding how blood-stage replication of Plasmodium could be targeted by vaccines and novel drugs.
Predicting quality and potency of monoclonal and natural antibodies
Rapid, simple and scalable assays for predicting antibody potency.
Vaccines against Plasmodium vivax and P. falciparum malaria
This involves identifying and prioritising candidate antigens for vaccine development.

Latest News

20 March, 2019

New insights into how the RTS,S malaria vaccine works

New discoveries by Burnet scientists may help inform the development of more effective malaria vaccines.
20 February, 2019

New PNG collaboration

Burnet Institute is collaborating with Papua New Guinea’s National Department of Health to improve health evidence, services and outcomes in PNG.

Upcoming Events

25 April, 2019

World Malaria Day

Malaria remains endemic in around 100 countries with more than three billion people at risk.

Our mission:

To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.

Contact Us

85 Commercial Road, Melbourne
VIC, 3004, Australia

E: reception@burnet.edu.au
T: +61 3 9282 2111

The Hub Site Map Careers

Disclaimer Privacy Policy Complaints Policy

This website was developed with the generous support of a donor.

Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.

Running to Save Lives

Support Our Work

Burnet Institute: Medical Research. Practical Action.

Equity through better health

Eliminate Malaria